Skip to main content
Emmanuel Antonarakis, MD, Oncology, Baltimore, MD, M Health Fairview University of Minnesota Medical Center

EmmanuelStylianosAntonarakisMD

Oncology Baltimore, MD

Genitourinary Oncology, Hematologic Oncology

Associate Professor of Oncology and Urology, Johns Hopkins University School of Medicine

Dr. Antonarakis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Antonarakis' full profile

Already have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 2004 - 2007
  • The University of Wales College of Medicine
    The University of Wales College of MedicineClass of 2003

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2021 - 2024
  • NC State Medical License
    NC State Medical License 2020 - 2022
  • MD State Medical License
    MD State Medical License 2007 - 2022
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
  • Top Doctors:Baltimore Area Castle Connolly, 2012
  • Top Doctors:Washington-Baltimore Castle Connolly, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer  
    Emmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology

Lectures

  • Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analy... 
    2019 ASCO Annual Meeting - 6/1/2019

Other

Authored Content

  • Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-Resistant Prostate Cancer in the Era of Precision OncologyApril 2018

Press Mentions

  • Study Shows How Novel Immunotherapy Helps Fight High-Risk Prostate Cancer, ET HealthWorld
    Study Shows How Novel Immunotherapy Helps Fight High-Risk Prostate Cancer, ET HealthWorldApril 8th, 2023
  • Genomic Profiling: Germline and Somatic Testing - What You Must Know Today - Emmanuel Antonarakis
    Genomic Profiling: Germline and Somatic Testing - What You Must Know Today - Emmanuel AntonarakisDecember 16th, 2021
  • With Rucaparib Approval, Prostate Cancer Joins the Precision Oncology Era
    With Rucaparib Approval, Prostate Cancer Joins the Precision Oncology EraSeptember 22nd, 2020
  • Join now to see all

Professional Memberships

Other Languages

  • French, Greek

Hospital Affiliations